11-47332896-G-T
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000256.3(MYBPC3):c.3408C>A(p.Tyr1136*) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000124 in 1,608,768 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000256.3 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MYBPC3 | NM_000256.3 | c.3408C>A | p.Tyr1136* | stop_gained | 31/35 | ENST00000545968.6 | NP_000247.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MYBPC3 | ENST00000545968.6 | c.3408C>A | p.Tyr1136* | stop_gained | 31/35 | 5 | NM_000256.3 | ENSP00000442795.1 | ||
MYBPC3 | ENST00000399249.6 | c.3408C>A | p.Tyr1136* | stop_gained | 30/34 | 5 | ENSP00000382193.2 |
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152192Hom.: 0 Cov.: 32
GnomAD4 exome AF: 6.87e-7 AC: 1AN: 1456576Hom.: 0 Cov.: 35 AF XY: 0.00 AC XY: 0AN XY: 723998
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152192Hom.: 0 Cov.: 32 AF XY: 0.0000134 AC XY: 1AN XY: 74352
ClinVar
Submissions by phenotype
Hypertrophic cardiomyopathy Pathogenic:4
Pathogenic, no assertion criteria provided | research | Agnes Ginges Centre for Molecular Cardiology, Centenary Institute | Dec 11, 2019 | The MYBPC3 Tyr1136Ter variant has been reported in a compound heterozygous infant born with an ventricular septal defect and LVNC, and a family history of HCM on both sides of the family. The Tyr1136Ter segregated on it's own in the probands mother who had a diagnosis of HCM (Haberer K, et al., 2014). It has also been reported in 4 HCM probands (Alfares AA, et al., 2015; Walsh R, et al., 2017). This variant is absent from the Genome Aggregation Database (http://gnomad.broadinstitute.org/). We have identified this variant in a HCM proband and this variant was found to segregate to an affected family member (Ingles et al., 2017). Based on the adapted ACMG guidelines (Kelly MA, et al., 2018) this variant results in loss of function of MYBPC3 (PVS1), is rare in the general population (PM2) and has been reported in at least two HCM probands (PS4_supporting), therefore we classify MYBPC3 Tyr1136Ter as "pathogenic". - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 17, 2023 | This sequence change creates a premature translational stop signal (p.Tyr1136*) in the MYBPC3 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MYBPC3 are known to be pathogenic (PMID: 19574547). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with hypertrophic cardiomyopathy (PMID: 24111713, 25262865, 27532257, 28408708). ClinVar contains an entry for this variant (Variation ID: 36611). For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Sep 21, 2011 | The Tyr1136X variant leads to a premature stop at codon 1136, which is predicted to lead to a truncated or absent protein. Loss of function variants are an esta blished mechanism of disease for the MYBPC3 gene. Therefore, Tyr1136X variant me ets our criteria for pathogenicity (http://pcpgm.partners.org/LMM). - |
Pathogenic, criteria provided, single submitter | clinical testing | All of Us Research Program, National Institutes of Health | Jul 19, 2023 | This variant changes 1 nucleotide in exon 31 of the MYBPC3 gene, creating a premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. This variant has been reported in four unrelated individuals affected with hypertrophic cardiomyopathy (PMID: 24111713, 28408708, 28615295, 33495596) and in an individual suspected to be affected with hypertrophic cardiomyopathy (PMID: 33673806). This variant has also been observed in compound heterozygous state with a known pathogenic MYBPC3 variant in an infant affected with left ventricular non-compaction (PMID: 25262865). Variant Tyr1136* was inherited from the parent who was affected with hypertrophic cardiomyopathy. This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Loss of MYBPC3 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic. - |
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Blueprint Genetics | Jun 21, 2018 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Dec 20, 2022 | Reported in a two-month-old male with LVNC who also harbors the c.2373dupG variant in the MYPBC3 gene; Y1136X was inherited from his mother who has a diagnosis of HCM, and c.2373dupG was inherited from his unaffected father (Haberer et al., 2014); Not observed at significant frequency in large population cohorts (gnomAD); Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; This variant is associated with the following publications: (PMID: 25262865, 24111713, 28408708, 34819141, 33673806, 27532257, 25611685) - |
Primary familial hypertrophic cardiomyopathy Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | May 26, 2015 | - - |
Cardiovascular phenotype Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Dec 22, 2023 | The p.Y1136* pathogenic mutation (also known as c.3408C>A), located in coding exon 31 of the MYBPC3 gene, results from a C to A substitution at nucleotide position 3408. This changes the amino acid from a tyrosine to a stop codon within coding exon 31. This variant has been detected in hypertrophic cardiomyopathy (HCM) cohorts (Berge KE et al. Clin. Genet., 2014 Oct;86:355-60; Ingles J et al. Circ Cardiovasc Genet, 2017 Apr;10; Walsh R et al. Genet. Med., 2017 02;19:192-203). This mutation was detected in trans with a second MYBPC3 mutation in an infant with non-compaction cardiomyopathy requiring heart transplant. The mother, who had only the p.Y1136* mutation, had a diagnosis of HCM (Haberer K et al. Can J Cardiol, 2014 Oct;30:1249.e1-3). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at